These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 14742540)

  • 21. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
    Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
    Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
    Jones TR; Obaldia N; Gramzinski RA; Charoenvit Y; Kolodny N; Kitov S; Davis HL; Krieg AM; Hoffman SL
    Vaccine; 1999 Aug; 17(23-24):3065-71. PubMed ID: 10462241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant.
    De Souza JB; Ling IT; Ogun SA; Holder AA; Playfair JH
    Infect Immun; 1996 Sep; 64(9):3532-6. PubMed ID: 8751895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.
    Ling IT; Ogun SA; Momin P; Richards RL; Garçon N; Cohen J; Ballou WR; Holder AA
    Vaccine; 1997 Oct; 15(14):1562-7. PubMed ID: 9330469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
    Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
    Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
    Burns JM; Flaherty PR; Nanavati P; Weidanz WP
    Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.
    Alaro JR; Partridge A; Miura K; Diouf A; Lopez AM; Angov E; Long CA; Burns JM
    Infect Immun; 2013 Oct; 81(10):3843-54. PubMed ID: 23897613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.
    Arévalo-Herrera M; Vera O; Castellanos A; Céspedes N; Soto L; Corradin G; Herrera S
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):21-7. PubMed ID: 21292874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii.
    Kringel H; Dubey JP; Beshah E; Hecker R; Urban JF
    Vet Parasitol; 2004 Aug; 123(1-2):55-66. PubMed ID: 15265571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
    Habjanec L; Halassy B; Tomasić J
    Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of antibody responses against Gnathostoma spinigerum in mice immunized with crude antigen formulated in CpG oligonucleotide and montanide ISA720.
    Intapan PM; Hirunpetcharat C; Kularbkaew C; Yutanawiboonchai W; Janwan P; Maleewong W
    Korean J Parasitol; 2013 Dec; 51(6):637-44. PubMed ID: 24516267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Poly(I:C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against Brucella melitensis infection in mice.
    Golshani M; Amani M; Amirzadeh F; Nazeri E; Davar Siadat S; Nejati-Moheimani M; Arsang A; Bouzari S
    Int Immunopharmacol; 2020 Jul; 84():106573. PubMed ID: 32454410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
    Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus).
    Rosa DS; Iwai LK; Tzelepis F; Bargieri DY; Medeiros MA; Soares IS; Sidney J; Sette A; Kalil J; Mello LE; Cunha-Neto E; Rodrigues MM
    Microbes Infect; 2006 Jul; 8(8):2130-7. PubMed ID: 16797207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis.
    Şahar EA; Can H; İz SG; Döşkaya AD; Kalantari-Dehaghi M; Deveci R; Gürüz AY; Döşkaya M
    BMC Infect Dis; 2020 Jul; 20(1):493. PubMed ID: 32650739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.
    Kawabata Y; Udono H; Honma K; Ueda M; Mukae H; Kadota J; Kohno S; Yui K
    Infect Immun; 2002 Nov; 70(11):6075-82. PubMed ID: 12379684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.